Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

作者：Mazen Noureddin, Stephen A. Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y. Sheikh, Shaheen Tomah, Julio Gutiérrez, Silvia Urbina, John J. Suschak, Randy A. Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M. Scot Roberts, Sarah Browne, M. Scott Harris · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)02114-2 · 被引用次数：28 · 研究领域：Liver Disease Diagnosis and Treatment、Diet and metabolism studies、Diet, Metabolism, and Disease